Browse > Article

Application of Toxicogenomic Technology for the Improvement of Risk Assessment  

Hwang, Myung-Sil (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research)
Yoon, Eun-Kyung (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research)
Kim, Ja-Young (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research)
Son, Bo-Kyung (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research)
Jang, Dong-Deuk (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research)
Yoo, Tae-Moo (Division of Risk Assessment, Department of Risk Assessment Research, National Institute of Toxicological Research)
Publication Information
Molecular & Cellular Toxicology / v.4, no.3, 2008 , pp. 260-266 More about this Journal
Abstract
Recently, there has been scientific discussion on the utility of -omics techniques such as genomics, proteomics, and metabolomics within toxicological research and mechanism-based risk assessment. Toxicogenomics is a novel approach integrating the expression analysis of genes (genomic) or proteins (proteomic) with traditional toxicological methods. Since 1999, the toxicogenomic approach has been extensively applied for regulatory purposes in order to understand the potential toxic mechanisms that result from chemical compound exposures. Therefore, this article's purpose was to consider the utility of toxicogenomic profiles for improved risk assessment, explore the current limitations in applying toxicogenomics to regulation, and finally, to rationalize possible avenues to resolve some of the major challenges. Based on many recent works, the significant impact toxicogenomic techniques would have on human health risk assessment is better identification of toxicity pathways or mode-of-actions (MOAs). In addition, the application of toxicogenomics in risk assessment and regulation has proven to be cost effective in terms of screening unknown toxicants prior to more extensive and costly experimental evaluation. However, to maximize the utility of these techniques in regulation, researchers and regulators must resolve many parallel challenges with regard to data collection, integration, and interpretation. Furthermore, standard guidance has to be prepared for researchers and assessors on the scientifically appropriate use of toxicogenomic profiles in risk assessment. The National Institute of Toxicological Research (NITR) looks forward to an ongoing role as leader in addressing the challenges associated with the scientifically sound use of toxicogenomics data in risk assessment.
Keywords
Risk assessment; Toxicogenomics; Toxic information;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 NRC (National Research Council). Science and judgment in risk assessment. Washington, DC; National Academy Press (1994)
2 Maggioli, J. et al. Toxicogenomic analysis methods for predivtive toxicology. J of Pharmaco and Toxicol Methods 53:31-37 (2006)   DOI   ScienceOn
3 Hamadeh, H. K. et al. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67:219-231 (2002b)   DOI   ScienceOn
4 Fielden, M. R. et al. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol Pathol 33:675-683 (2005)   DOI
5 Uetrecht, J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov Devel 4:55-59 (2001)
6 Masubuchi, Y., Nakayama, S. & Horie, T. Role of mitochondrial permeability transition in diclofenacinduced hepatocyte injury in rats. Hepatology 35:544-551 (2002)   DOI   ScienceOn
7 EPA. Arsenic, inorganic. CASRN 7440-38-2. Integrated Risk Information System (IRIS). Available: http://www.epa.gov/iris/subst/0278.htm(1998b)
8 Ulrich, R. G. et al. Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem Biol Interact 134: 251-270 (2001)   DOI   ScienceOn
9 Salerno, R. A. & Lesko, L. J. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5:503-505 (2004)   DOI   ScienceOn
10 Iannaccone, P. M. Toxicogenomics: "the call of the wild chip". Environ Health Perspect 109:8-11 (2001)   DOI
11 Aardema, M. J. & MacGregor, J. T. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat Res 499: 13-25 (2002)   DOI   ScienceOn
12 FDA. Guidance for industry Pharmacogenomic data submissions. Washington, DC: Food and Drug Administration. Available: www.fda.gov/cder/guidance/ 6400fnl.pdf (2005)
13 Yang, Y., Blomme, E. A. G. & Waring, J. F. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 150:71-85 (2004)   DOI   ScienceOn
14 Nie, A. Y. et al. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 45:914-933 (2006)   DOI   ScienceOn
15 Ulrich, R. & Friend, S. H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat Rev Drug Discov 1:84-88 (2002)   DOI
16 Boelsterli, U. A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307-322 (2003)   DOI   ScienceOn
17 Kultima, K. et al. Valproic acid teratogenicity: A toxicogenomics approach. Environ Health Perspect 112: 1225-1235 (2004)   DOI   ScienceOn
18 Hansch, C. et al. The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett 79:45-53 (1995)   DOI   ScienceOn
19 Jiang, Y. et al. Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles. J Trans Med 5:47-54 (2007)   DOI   ScienceOn
20 Fielden, M. R. & Zacharewski, T. R. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol Sci 60:6-10 (2001)   DOI   ScienceOn
21 Tong, W. et al. Assessment of prediction confidence and domain extrapolation of two structure-activity relationship models for predicting estrogen receptor binding activity. Environ Health Perspect 112:1249-1254 (2004)   DOI   ScienceOn
22 Guerreiro, N. et al. Toxicogenomics in drug development. Toxicol Pathol 31:471-479 (2003)   DOI
23 International Agency for Research on Cancer, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Overall evaluations of carcinogenicity: An updating of IARC monographs Vol. 1-42, Supplement 7. Lyon, France: IARC Press. (1987)
24 Smith, L. L. Key challenges for toxicologists in the 21st century. Trends Pharmacol Sci 22:281-285 (2001)   DOI   ScienceOn